← Leaderboards
Maurizio Pellecchia
University Of California Riverside
$35,980,620
Attributed
$35,980,620
Total exposure
23
Grants
21
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $5.5M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$35,980,620 · 23
By mechanism
R01$14,923,445 · 5
P01$8,242,277 · 3
U01$5,122,124 · 1
R24$2,940,388 · 1
S10$1,444,784 · 1
U54$1,323,445 · 4
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Structure”
- David Heimbrook · Leidos Biomedical Research, Inc.$475,333,582
- Barton F Haynes · Duke University$444,977,767
- Lawrence Corey · Fred Hutchinson Cancer Center$334,646,086
- Gary D Acton · University Of California-Davis$320,373,312
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Michael David Hughes · Harvard University D/B/A Harvard School Of Public Health$315,257,203
Research focus
StructureInnovationDesignSignal TransductionCellsLaboratoriesBaseIn VivoPharmaceutical PreparationsProteinsMediatingProgramsPropertyIn VitroAffinityLeadApoptosisClinical TrialsInhibitor/AntagonistFamilyDrug DiscoverySmall MoleculeAffectCollaborations
Grant awards (79)
Targeting the EphA4 in motor neuron disease: a structure-based approach$397,551
R01 · FY2025 · NS · contact PI
Research Education$169,600
U54 · FY2025 · CA · contact PI
Full Project 2$169,600
U54 · FY2025 · CA · contact PI
Mcl-1/Bfl-1 in apoptosis and signal transduction: a structure/function approach$411,639
R01 · FY2024 · CA · contact PI
Targeting the EphA4 in motor neuron disease: a structure-based approach$382,801
R01 · FY2024 · NS · contact PI
Full Project 2$212,894
U54 · FY2024 · CA · contact PI
Research Education$124,188
U54 · FY2024 · CA · contact PI
Mcl-1/Bfl-1 in apoptosis and signal transduction: a structure/function approach$424,639
R01 · FY2023 · CA · contact PI
Targeting the EphA4 in motor neuron disease: a structure-based approach$408,514
R01 · FY2023 · NS · contact PI
Full Project 2$224,278
U54 · FY2023 · CA · contact PI
Core 2: Research Education$146,080
U54 · FY2023 · CA · contact PI
Project 2$146,080
U54 · FY2023 · CA · contact PI
Research Education$130,725
U54 · FY2023 · CA · contact PI
Targeting the EPhA4 in motor neuron disease: a structure-based approach$450,206
R01 · FY2022 · NS · contact PI
Mcl-1/Bfl-1 in apoptosis and signal transduction: a structure/function approach$424,639
R01 · FY2022 · CA · contact PI
2/2 Drug Development and Capacity Building: A UCR/CoH-CCC Partnership (Education Core)$35,571
P20 · FY2022 · CA · contact PI
Targeting the EPhA4 in motor neuron disease: a structure-based approach$450,115
R01 · FY2021 · NS · contact PI
Mcl-1/Bfl-1 in apoptosis and signal transduction: a structure/function approach$433,304
R01 · FY2021 · CA · contact PI
2/2 Drug Development and Capacity Building: A UCR/CoH-CCC Partnership (Education Core)$28,227
P20 · FY2021 · CA · contact PI
Targeting the EPhA4 in motor neuron disease: a structure-based approach$451,694
R01 · FY2020 · NS · contact PI
Mcl-1/Bfl-1 in apoptosis and signal transduction: a structure/function approach$433,304
R01 · FY2020 · CA · contact PI
2/2 Drug Development and Capacity Building: A UCR/CoH-CCC Partnership (Education Core)$35,571
P20 · FY2020 · CA · contact PI
Targeting the EPhA4 in motor neuron disease: a structure-based approach$453,229
R01 · FY2019 · NS · contact PI
2/2 Drug Development and Capacity Building: A UCR/CoH-CCC Partnership (Education Core)$35,571
P20 · FY2019 · CA · contact PI
Targeting the EPhA4 in motor neuron disease: a structure-based approach$468,592
R01 · FY2018 · NS · contact PI
Mcl-1 in apoptosis and signal transduction: a structure/function approach$474,252
R01 · FY2016 · CA · contact PI
Mcl-1 in apoptosis and signal transduction: a structure/function approach$521,604
R01 · FY2015 · CA · contact PI
Mcl-1 in apoptosis and signal transduction: a structure/function approach$505,956
R01 · FY2014 · CA · contact PI
Targeting apoptosis via chemical design of Bcl-2 antagonists$380,712
R01 · FY2014 · CA · contact PI
Targeted Drug Delivery$357,587
P01 · FY2014 · CA · contact PI
Targeting Hypoxia-Induced Cancer-Cell Adaptation by Direct Inhibition of Akt and$529,342
P01 · FY2013 · CA · contact PI
Mcl-1 in apoptosis and signal transduction: a structure/function approach$490,308
R01 · FY2013 · CA · contact PI
Targeting apoptosis via chemical design of Bcl-2 antagonists$368,938
R01 · FY2013 · CA · contact PI
Targeted Drug Delivery$346,984
P01 · FY2013 · CA · contact PI
Targeting bacterial phosphatases for novel anti-bacterial agents.$292,500
R21 · FY2013 · AI · contact PI
Targeting Hypoxia-Induced Cancer-Cell Adaptation by Direct Inhibition of Akt and$549,069
P01 · FY2012 · CA · contact PI
Mcl-1 in apoptosis and signal transduction: a structure/function approach$545,354
R01 · FY2012 · CA · contact PI
Targeted Drug Delivery$400,886
P01 · FY2012 · CA · contact PI
Targeting apoptosis via chemical design of Bcl-2 antagonists$384,435
R01 · FY2012 · CA · contact PI
Targeting bacterial phosphatases for novel anti-bacterial agents.$243,750
R21 · FY2012 · AI · contact PI
Targeting Hypoxia-Induced Cancer-Cell Adaptation by Direct Inhibition of Akt and$485,596
P01 · FY2011 · CA · contact PI
Targeting apoptosis via chemical design of Bcl-2 antagonists$384,435
R01 · FY2011 · CA · contact PI
Targeted Drug Delivery$296,691
P01 · FY2011 · CA · contact PI
Development of an effective therapy against post-exposure Anthrax$817,642
U01 · FY2010 · AI · contact PI
JIP mimics for the treatment of diabetes$751,704
R24 · FY2010 · DK · contact PI
Targeting Hypoxia-Induced Cancer-Cell Adaptation by Direct Inhibition of Akt and$502,289
P01 · FY2010 · CA · contact PI
Anti-apoptotic compounds for treatment of brain ischemia$463,653
R01 · FY2010 · HL · contact PI
Novel anti-toxin compounds against Yersinia infections$434,250
R56 · FY2010 · AI · contact PI
Targeting apoptosis via chemical design of Bcl-2 antagonists$396,325
R01 · FY2010 · CA · contact PI
Targeted Drug Delivery$249,001
P01 · FY2010 · CA · contact PI
Development of an effective therapy against post-exposure Anthrax$828,365
U01 · FY2009 · AI · contact PI
JIP mimics for the treatment of diabetes$730,293
R24 · FY2009 · DK · contact PI
Potent and Safe Inhibitors of B. anthracis Lethal Factor$680,436
R01 · FY2009 · AI · contact PI
Targeting Hypoxia-Induced Cancer-Cell Adaptation by Direct Inhibition of Akt and$492,539
P01 · FY2009 · CA · contact PI
Anti-apoptotic compounds for treatment of brain ischemia$463,653
R01 · FY2009 · HL · contact PI
Development of an effective therapy against post-exposure Anthrax$1,147,755
U01 · FY2008 · AI · contact PI
Inhibitor Design and Synthesis$779,505
P01 · FY2008 · AI · contact PI
JIP mimics for the treatment of diabetes$709,503
R24 · FY2008 · DK · contact PI
Potent and Safe Inhibitors of B. anthracis Lethal Factor$626,723
R01 · FY2008 · AI · contact PI
Anti-apoptotic compounds for treatment of brain ischemia$463,653
R01 · FY2008 · HL · contact PI
Novel Chemical Probes Targeting the FRB Domain of mTOR$25,000
R03 · FY2008 · MH · contact PI
NMR spectroscopy instrumentation for probing intermolecular interations$1,444,784
S10 · FY2007 · RR · contact PI
Development of an effective therapy against post-exposure Anthrax$1,138,413
U01 · FY2007 · AI · contact PI
Inhibitor Design and Synthesis$772,834
P01 · FY2007 · AI · contact PI
JIP mimics for the treatment of diabetes$748,888
R24 · FY2007 · DK · contact PI
Potent and Safe Inhibitors of B. anthracis Lethal Factor$620,855
R01 · FY2007 · AI · contact PI
Anti-apoptotic compounds for treatment of brain ischemia$463,653
R01 · FY2007 · HL · contact PI
Allosteric JNK modulators for the treatment of diabetes$260,228
R21 · FY2007 · DK · contact PI
Novel Chemotypes Against Influenza A Virus$25,000
R03 · FY2007 · DA · contact PI
Development of an effective therapy against post-exposure Anthrax$1,189,949
U01 · FY2006 · AI · contact PI
Inhibitor Design and Synthesis$806,345
P01 · FY2006 · AI · contact PI
Potent and Safe Inhibitors of B. anthracis Lethal Factor$620,773
R01 · FY2006 · AI · contact PI
Anti-apoptotic compounds for treatment of brain ischemia$477,500
R01 · FY2006 · HL · contact PI
Allosteric JNK modulators for the treatment of diabetes$252,250
R21 · FY2006 · DK · contact PI
Inhibitor Design and Synthesis$788,603
P01 · FY2005 · AI
MOLECULAR DESIGN$125,239
U19 · FY2005 · CA
BcI-2 family proteins as targets for chemoprevention an*$95,500
R03 · FY2005 · CA
Inhibitor Design and Synthesis$885,006
P01 · FY2004 · AI
Bcl-2 proteins-targets for chemoprevention /Chemotherapy$95,500
R03 · FY2004 · CA